Relevant bibliographies by topics / Hormone therapy

Academic literature on the topic 'Hormone therapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hormone therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hormone therapy"

1

Mel’nikov, A. P., and V. A. Fedorenko. "Risk of thromboembolic complications during hormone therapy." Clinical Medicine (Russian Journal) 100, no. 1 (April 22, 2022): 11–17. http://dx.doi.org/10.30629/0023-2149-2022-100-1-11-17.

Full text
Abstract:
The review presents modern data of the effect of hormonal contraceptives and hormone replacement therapy drugs on the risk of thromboembolic complications. The effect of components of the drugs and their dosages on the hemostasis system is presented, the use of hormonal therapy in women with extragenital diseases is discussed, the ways of reducing the thrombogenic risk of hormones with their mandatory use are debated.
APA, Harvard, Vancouver, ISO, and other styles
2

Mitra, Saikat, Mashia Subha Lami, Avoy Ghosh, Rajib Das, Trina Ekawati Tallei, Fatimawali, Fahadul Islam, et al. "Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?" Cancers 14, no. 3 (February 1, 2022): 759. http://dx.doi.org/10.3390/cancers14030759.

Full text
Abstract:
In recent years, hormone therapy has been shown to be a remarkable treatment option for cancer. Hormone treatment for gynecological cancers involves the use of medications that reduce the level of hormones or inhibit their biological activity, thereby stopping or slowing cancer growth. Hormone treatment works by preventing hormones from causing cancer cells to multiply. Aromatase inhibitors, anti-estrogens, progestin, estrogen receptor (ER) antagonists, GnRH agonists, and progestogen are effectively used as therapeutics for vulvar cancer, cervical cancer, vaginal cancer, uterine cancer, and ovarian cancer. Hormone replacement therapy has a high success rate. In particular, progestogen and estrogen replacement are associated with a decreased incidence of gynecological cancers in women infected with human papillomavirus (HPV). The activation of estrogen via the transcriptional functionality of ERα may either be promoted or decreased by gene products of HPV. Hormonal treatment is frequently administered to patients with hormone-sensitive recurring or metastatic gynecologic malignancies, although response rates and therapeutic outcomes are inconsistent. Therefore, this review outlines the use of hormonal therapy for gynecological cancers and identifies the current knowledge gaps.
APA, Harvard, Vancouver, ISO, and other styles
3

Pines, Amos. "Where postmenopausal hormone therapy stands today." HORMONES 8, no. 4 (October 15, 2009): 227–31. http://dx.doi.org/10.14310/horm.2002.1241.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Beyer-Westendorf, Jan, Rupert Bauersachs, Viola Hach-Wunderle, Rainer B. Zotz, and Hannelore Rott. "Sex hormones and venous thromboembolism – from contraception to hormone replacement therapy." Vasa 47, no. 6 (October 1, 2018): 441–50. http://dx.doi.org/10.1024/0301-1526/a000726.

Full text
Abstract:
Abstract. The use of sex hormones such as combined oral contraceptives (COC) or hormone replacement therapy (HRT) increases the risk for venous thromboembolism (VTE) considerably, especially in patients with an increased intrinsic risk for thromboembolic complications. Despite public and media attention and increasing scientific evidence, prescription patterns seem to be hard to change. It is well recognized that the patient’s baseline risk is the most relevant factor in the absolute risk for developing VTE. The relative risk increase associated with sex hormones, depends on the type and dosage of hormones, the route of application (oral, vaginal, transdermal), and for COC, on the specific combination of oestrogen and gestagen components. Consequently, a careful decision for or against any specific type of hormone treatment needs to be based on an assessment of the patient’s risk profile (disposition) as well as on the treatment-associated risks and benefits (exposition). This review discusses the most common sex hormone treatments in contraception and HRT, the relevance for VTE risk patients, and strategies to counsel patients with regard to hormone use according to their risk profiles. Keywords: Oral contraceptives, hormonal contraception, hormone replacement therapy, venous thromboembolism
APA, Harvard, Vancouver, ISO, and other styles
5

Zheng, H., J. J. Kavanagh, W. Hu, Q. Liao, and S. Fu. "Hormonal therapy in ovarian cancer." International Journal of Gynecologic Cancer 17, no. 2 (2007): 325–38. http://dx.doi.org/10.1111/j.1525-1438.2006.00749.x.

Full text
Abstract:
Ovarian carcinoma continues to be the leading cause of death due to gynecological malignancy. Epidemiologic studies indicate that steroid hormones play roles in ovarian carcinogenesis. Gonadotropins, estrogen, and androgen may be causative factors, while gonadotropin-releasing hormone and progesterone may be protective factors in ovarian cancer pathogenesis. Experimental studies have shown that hormonal receptors are expressed in ovarian cancer cells and mediate the growth-stimulatory or growth-inhibitory effects of the hormones on these cells. Hormonal therapeutic agents have been evaluated in several clinical trials. Most of these trials were conducted in patients with recurrent or refractory ovarian cancer, with modest efficacy and few side effects. Better understanding of the mechanisms through which hormones affect cell growth may improve the efficacy of hormonal therapy. Molecular markers that can reliably predict major clinical outcomes should be investigated further in well-designed trials
APA, Harvard, Vancouver, ISO, and other styles
6

Dumanić, Klara, Jelena Marušić, and Ivana Mudnić. "Influence of oral hormonal contraception on the concentration of anti-Müllerian and reproductive hormones in patients with polycystic ovary syndrome." St open 4 (December 6, 2023): 1–9. http://dx.doi.org/10.48188/so.4.18.

Full text
Abstract:
Aim: To investigate the effects of three-month use of oral hormonal contraception (OHC) on hormonal status and ovarian reserve indicator (anti-Müllerian hormone, AMH) in patients with polycystic ovary syndrome (PCOS).Methods: 19 patients with diagnosed PCOS and clinical and laboratory signs of hyperandrogenism without additional comorbidities and co-medication were included in the study. All participants received therapy with the same oral hormonal contraceptive (fixed combination of 0.035 mg ethinyl estradiol and 2 mg cyproterone acetate). The main outcomes were the concentrations of reproductive hormones measured before starting therapy and in the first cycle following therapy. Hormone concentrations were analysed using the immunochemical electrochemiluminescence (ECLIA) method.Results: Initial concentrations of total and free testosterone and AMH were elevated, while initial concentrations of other reproductive hormones were within reference values. By applying the therapy, the concentrations of AMH, luteinizing hormone (LH) and estradiol decreased by more than 20% and those of free testosterone by 85%. The concentration of sex hormone binding globulin (SHBG) increased by 44%.Conclusions: Three months of oral hormonal contraception with 35 μg ethinyl estradiol and 2 mg cyproterone acetate reduced elevated concentrations of AMH and free testosterone in PCOS patients. The decrease in serum AMH concentration indicates a temporary interruption of folliculogenesis as well as the selection of follicles from preantral to antral, and the decrease in androgens has a positive effect on the clinical condition and symptoms of patients with PCOS.
APA, Harvard, Vancouver, ISO, and other styles
7

Ch, Renuka Devi, and Jhansi Rani N. "Impact of Yoga therapy on hormonal imbalance in women with Polycystic Ovarian Disease." International Journal of Ayurvedic Medicine 14, no. 1 (April 4, 2023): 206–12. http://dx.doi.org/10.47552/ijam.v14i1.3357.

Full text
Abstract:
The current study aims to evaluate the impact of yoga therapy on hormonal imbalance in PCOS affected women. An empirical study was conducted on 25 women having been diagnosed with PCOS condition. The study used pre and post design. Before starting allopathic medication participants were explained about yoga therapy and participants in the study voluntarily agreed to participate in this study without using medication. Written consent was obtained from the participants. Testosterone, Prolactin, Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH), were selected as dependent variables for this study. Before introducing the yoga therapy intervention, baseline hormonal values were collected through blood tests. All the 25 participants practiced yoga protocol specially designed for PCOS condition, for a duration of 12 weeks. At the end of 12 weeks the participant took the blood test in the laboratory for hormonal levels of PCOS related hormones selected for this study. Baseline data was compared with Post data. The impact of yoga therapy on the hormonal imbalance was statistically analysed through paired t-test. The statistical analysis yielded following t values: Serum Testosterone 21.52 (P <0.001), Serum Prolactin 22.13 (P<0.001), Serum LH 30.10 (P<0.001), and Serum FSH 14.16 (P<0.001). The impact of yoga therapy intervention on hormones related to PCOS condition was found to be significantly positive. The results imply that regular yoga practice can be an effective therapy for women with PCOS, especially for correcting imbalance in hormone levels related to PCOS.
APA, Harvard, Vancouver, ISO, and other styles
8

WARREN, MICHELLE P. "Hormone Therapy." Clinical Obstetrics and Gynecology 47, no. 2 (June 2004): 412. http://dx.doi.org/10.1097/00003081-200406000-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Hormone Therapy." Clinical Obstetrics and Gynecology 47, no. 2 (June 2004): 500–501. http://dx.doi.org/10.1097/00003081-200406000-00025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

PINKERTON, JOANN V. "Hormone Therapy." Clinical Obstetrics and Gynecology 61, no. 3 (September 2018): 447–53. http://dx.doi.org/10.1097/grf.0000000000000383.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hormone therapy"

1

陳蒓 and Tzun Rachel Chan. "Growth hormone therapy for growth hormone deficiency." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2001. http://hub.hku.hk/bib/B31970308.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chan, Tzun Rachel. "Growth hormone therapy for growth hormone deficiency." Hong Kong : University of Hong Kong, 2001. http://sunzi.lib.hku.hk/hkuto/record.jsp?B22926288.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Coo, Helen. "Knowledge of hormone therapy and its impact on adherence to hormone therapy for prevention." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape8/PQDD_0003/MQ42601.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Habiba, Marwan A. "Endometrial responses to hormone replacement therapy." Thesis, University of Leicester, 1998. http://hdl.handle.net/2381/30471.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ödmark, Inga-Stina. "Hormone replacement therapy : benefits and adverse effects." Doctoral thesis, Umeå universitet, Obstetrik och gynekologi, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-243.

Full text
Abstract:
Background: Numerous studies have shown that estrogen replacement therapy (ERT) is an effective treatment for vasomotor symptoms, insomnia and vaginal dryness. Beneficial effects have also been shown on lipid patterns and on the incidence of osteoporotic fractures. As ERT increases the risk of endometrial adenocarcinoma, combinations with various progestogens have been developed in order to protect the endometrium. However, the addition of progestogens tends to reduce the beneficial effects of estrogens on mood, cognition and lipid metabolism. The added progestogen often causes side effects such as irritability and depression. There is evidence that the effect on wellbeing varies between women and with the type of progestogen used. Women who prefer to avoid withdrawal bleedings can be given continuous combined hormone replacement therapy (HRT). Unfortunately, irregular bleedings are common at the beginning of treatment and reduces compliance. Recently, several studies have reported an increased risk of breast cancer and venous thrombosis, and therefore long-term treatment with HRT for women without climacteric symptoms is no longer recommended. The ongoing debate has, for the time being, resulted in a recommendation that improving quality of life (QoL) by treatment of climacteric symptoms should be the only indication for prescribing HRT. Aims and methods: The aims of the study were to investigate bleeding patterns, changes in wellbeing at onset and during long-term treatment, and lipid and lipoprotein profiles with two different types of continuous combined HRT. In addition, women starting, and women switching from mainly sequential HRT were compared. The design was a randomised, double-blind, one year, prospective, multicentre study including 249 healthy postmenopausal women who were given continuous daily oral treatment with either combined 0.625mg conjugated estrogen (CE) and 5mg medroxyprogesterone acetate (MPA) or combined 2mg 17β - estradiol (E2) and 1mg norethisterone acetate (NETA). Bleedings, if any, were recorded daily throughout the study. The main outcome measures (changes in wellbeing and climacteric symptoms) consisted of daily ratings of 12 items on a validated symptom scale. Serum concentrations of lipids and lipoproteins were measured at baseline and after one year of treatment. Results and conclusions: The majority of drop-outs were confined to the first three months, and the main reasons were bleedings and/or decreased wellbeing. Drop-outs were three times more common in the E2/NETA group. During the first month, 67% of the women reported irregular bleedings. The number of bleeding days decreased on both treatments during the first four months. Treatment with CE/MPA resulted in less irregular bleedings and a shorter time to amenorrhoea compared to E2/NETA. As expected, "starters" experienced more sweats than "switchers" at the onset of treatment, but both groups improved significantly. Side effects such as breast tenderness, swelling, depression and irritability appeared during the first treatment week in both groups. The side effects of HRT appeared much more quickly than the benefits and were more frequent in women with a history of premenstrual syndrome (PMS). Breast tenderness was more common in the E2/NETA group throughout the whole study period. Apart from that, there were no differences between the two treatment regimens as regards effects on well-being at the end of the study. Lipoprotein(a) levels, an important risk factor for cardiovascular disease, decreased in both treatment groups. Triglyceride levels increased in women treated with CE/MPA, and levels of total cholesterol, high density lipoprotein and low density lipoprotein fell in the E2/NETA group. In conclusion, treatment with E2/NETA caused more bleeding problems than treatment with CE/MPA. CE/MPA was better tolerated than E2/NETA at the beginning of the study, but among the women remaining in the study there was no difference in QoL between the two treatment groups. HRT counselling should take into account that a history of PMS increases the likelihood of side effects and that these may precede any beneficial effects. Both treatments produced beneficial effects on lipid and lipoprotein levels, and neither of the regimens was superior in this respect.
APA, Harvard, Vancouver, ISO, and other styles
6

Lundström, Eva. "Mammographic breast density and postmenopausal hormone therapy /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-581-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ödmark, Inga-Stina. "Hormone replacement therapy : benefits and adverse effects /." Umeå : Univ, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-243.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Björn, Inger. "Hormone replacement therapy and effects on mood." Doctoral thesis, Umeå universitet, Obstetrik och gynekologi, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-94115.

Full text
Abstract:
Background: During the past 5 decades, hormone replacement therapy (HRT) has been used, and appreciated for its beneficial effects, by millions of women in their menopause. As treatment for climacteric symptoms, estrogen is outstanding, and effects on hot flushes, vaginal dryness, and insomnia have been widely documented. The increased risks of venous thrombosis and breast cancer, however, restrict the use of estrogen. Estrogen treatment in women with a remaining uterus includes a progestin, added to protect the endometrium from hyperplasia and malignancies. The long-standing clinical impression, that progestin addition negatively influences mood, has been discussed in previous studies. Mood deterioration is, however, not mortal, although mood is important to the wellbeing and daily functioning of women treated with hormones. Studies of the mental side effects of HRT add to our understanding of steroid effects in the brain. Aims and methods: In our studies, we aimed to establish to what extent negative side effects cause women to discontinue HRT, and find out which drug compounds lead to mood deterioration. The questions asked were whether the type and dose of progestin and the estrogen dose during the progestin addition influence the mood and physical symptoms during sequential HRT. Compliance with HRT and reasons for discontinuing the therapy were evaluated in a retrospective longitudinal follow-up study. Treatment effects were studied in three randomized, double-blind, cross-over trials. During continuous estrogen treatment, effects of sequential addition of a progestin were studied by comparing two different progestins, medroxyprogesterone acetate (MPA) andnorethisterone acetate (NETA), comparing different doses of the same progestin, MPA, and comparing two doses of estrogen during addition of the same dose of MPA. The main outcome measure was the daily rating on mood and physical symptoms kept by the participants throughout the studies. The clinical trials were carried out at three gynecological centers in northern Sweden. Results and conclusions: Besides fear of cancer and a wish to determine whether climacteric symptoms had meanwhile disappeared, negative side effects was the most common reason or discontinuing HRT. Tension in the breasts, weight gain, a depressed mood, abdominal bloating, and irritability were the most important side effects seen both in women who continued HRT and in women who had discontinued the therapy. In our clinical trials, we showed that addition of a progestin to estrogen treatment induces cyclic mood swings characterized by tension, irritability, and depression, as well as increased breast tension, bloatedness, and hot flushes. Women with a history of premenstrual syndrome (PMS) appeared to be more sensitive to the progestin addition and responded with lower mood scores compared with women without previous PMS. In our studies, MPA provoked depressed mood to a lesser extent than did NETA. Surprisingly, the higher dose of MPA (20 mg) enhanced the mood, compared with 10 mg, when added to estrogen treatment. In women continuously treated with 3 mg estradiol, mood and physical symptoms worsened during the progestin addition, as compared with treatment with 2 mg estradiol. The negative side effects seen during sequential HRT have much in common with symptoms seen in the premenstrual dysphoric disorder (PMDD), which is a psychoneuroendocrine disorder with psychiatric expression. Explanations for treatment effects on mood are likely to be found in drug interactions with neurotransmitter systems of the brain.

Diss. (sammanfattning) Umeå : Umeå universitet, 2003


digitalisering@umu
APA, Harvard, Vancouver, ISO, and other styles
9

Homer, Natalie. "Erythocyte oxidative stress : focus on hormone replacement therapy." Thesis, University of Strathclyde, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273852.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Khorsheed, Sarah. "Kartläggning av användningsmönstret av Menopausal Hormone Therapy (MHT)." Thesis, Uppsala universitet, Institutionen för farmaci, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-432290.

Full text
Abstract:
Background Menopausal hormone therapy (MHT) is used to treat menopausal symptoms. The use of MHT decreased after the Women's Health Initiative (WHI) study which proved an increased risk of stroke and breast cancer. In 2019 the Swedish Medical Products Agency was commissioned to update the treatment recommendations of MHT. Aim  To conduct a review of studies analyzing the use of MHT through the literature, and to describe the use of MHT in Sweden.  Methods A literature study assessing published studies on MHT use from different countries, by using PubMed database and publications found at various Swedish authorities’ websites such as the Swedish Medical Products Agency and the National Board of Health and Welfare between 2003 and 2020 that fulfilled the purpose.A register study to analyze MHT use in the Swedish female population between 2008 – 2019 for women between 40 – 59 years. The databases used was the National Board of Health and Welfare's patient register and the Swedish Prescribed Drug Register Results There is a large variation in MHT utilization between countries due to differences in guidelines and other factors.In Sweden, the use of MHT was low in comparison with other countries, women had more knowledge about the treatment and prescribers followed the Swedish Medical Products Agency's recommendations.In 2019, the increase in patients diagnosed with menopause was twice as high as it was in 2008. in addition, the use of (MHT) in Sweden increased in the period 2017 - 2020. The most widely used MHT group was estrogen. Conclusions MHT use has increased in the Swedish population between 2017 and 2020, further knowledge of the benefit- risk profile is needed
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Hormone therapy"

1

Sherif, Katherine. Hormone Therapy. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6268-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Meikle, A. Wayne, ed. Hormone Replacement Therapy. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-700-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

T, Khaw K., ed. Hormone replacement therapy. Edinburgh: Churchill Livingstone, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

P, Swartz Donald, ed. Hormone replacement therapy. Baltimore: Williams & Wilkins, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

L, Page M., Duphar Medical Relations, and Royal College of Obstetricians and Gynaecologists., eds. Hormone replacement therapy. Southampton: Duphar Medical Relations, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wayne, Meikle A., ed. Hormone replacement therapy. Totowa, N.J: Humana Press, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Burger, Henry G., ed. Sex Hormone Replacement Therapy. Boston, MA: Springer US, 2000. http://dx.doi.org/10.1007/978-1-4757-6507-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hawkins, Amy Lee. Replacing hormone replacements: Your bioidentical hormone solution. North Branch, MN: Sunrise River Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kato, J., H. Minaguchi, and Y. Nishino, eds. Hormone Replacement Therapy and Osteoporosis. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-662-04021-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

R, Johnson Susan, ed. Menopause and hormone replacement therapy. Philadelphia: Saunders, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Hormone therapy"

1

Orbell, Sheina, Havah Schneider, Sabrina Esbitt, Jeffrey S. Gonzalez, Jeffrey S. Gonzalez, Erica Shreck, Abigail Batchelder, et al. "Hormone Therapy." In Encyclopedia of Behavioral Medicine, 981. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_100814.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pratt, Alexander. "Hormone Therapy." In The Perioperative Medicine Consult Handbook, 125–29. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-19704-9_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Weber, Georg F. "Hormone Therapy." In Molecular Therapies of Cancer, 303–32. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-13278-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rabe, T., B. Runnebaum, and S. Kellermeier-Wittlinger. "Hormone Therapy." In Gynecological Endocrinology and Reproductive Medicine, 55–130. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60390-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Smith, P. H. "Hormone Therapy." In Testicular Cancer and Other Tumors of the Genitourinary Tract, 455–61. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2453-9_57.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sherif, Katherine. "FAQ: Definitions of Menopause and Biological Actions of Sex Steroids." In Hormone Therapy, 3–15. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6268-2_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sherif, Katherine. "Hormone Therapy: Monitoring Effects and Side Effects." In Hormone Therapy, 79–83. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6268-2_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sherif, Katherine. "FAQ: Evaluation of Abnormal Menstrual Bleeding." In Hormone Therapy, 85–87. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6268-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sherif, Katherine. "FAQ: Ending HT." In Hormone Therapy, 89–91. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6268-2_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sherif, Katherine. "FAQ: HT and Other Conditions: Uterine Fibroids, Autoimmune disease, Hypothyroidism, and History of Breast Cancer." In Hormone Therapy, 93–95. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6268-2_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hormone therapy"

1

Bunting, Haley A., Ryan T. Cassilly, Brian Jin, Christopher S. Ahmad, Louis U. Bigliani, William N. Levine, and Thomas R. Gardner. "Effect of Hormone Therapy on Tensile Strain of the Macaque Inferior Glenohumeral Ligament." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53531.

Full text
Abstract:
The effect of hormone treatment on the material properties of ligaments has been extensively studied for the anterior cruciate ligament (ACL). However, there have been few studies on the effects of hormones on the material properties of the shoulder. Shoulder ligaments contribute to overall shoulder stability, and a change in ligament properties could contribute to a change in overall shoulder laxity. Cynomolgus monkeys have served as nonhuman primate models in studies examining the effects of hormone replacement therapy on the cardiovascular system, as well as serving as a model for menopause, reproductive support structures, the knee joint and shoulder joint. The cynomolgus macaques are commonly used for studies involving hormone replacement therapy because they have 28-day menstrual cycles with very similar hormonal patterns to that of women. This study uses female cynomologus macaque (Macaca fascicularis) monkeys as an animal model of the human shoulder to determine if estrogen has an effect on the strain distribution of the inferior glenohumeral ligament (IGHL).
APA, Harvard, Vancouver, ISO, and other styles
2

Gardner, Thomas R., Ryan T. Cassilly, Brian Jin, Anuli N. Mkparu, Christoper S. Ahmad, Louis U. Bigliani, and William N. Levine. "Effect of Estrogen on Viscoelastic Properties of the Anterior Pouch of the Macaque Animal Model of the Inferior Glenohumeral Ligament." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206835.

Full text
Abstract:
The effect of hormone treatment on the material properties of ligaments has been extensively studied for the anterior cruciate ligament (ACL). However, there have been very few studies on the effects of hormones on the material properties of the shoulder. These shoulder ligaments contribute to overall shoulder stability, and a change in ligament properties could contribute to a change in overall shoulder laxity. This study uses female cynomologus macaque (Macaca fascicularis) monkeys as an animal model of the human shoulder to determine if estrogen has an effect on the viscoelastic properties of the anterior pouch of the inferior glenohumeral ligament (IGHL). Cynomolgus monkeys have served as nonhuman primate models in several studies, including monkey models of menopause, the effects of hormone replacement therapy on the cardiovascular system, reproductive support organs, and the knee joint. The cynomolgus macaques are commonly used for studies involving hormone replacement therapy because they have 28-day menstrual cycles with very similar hormonal patterns to that of women.
APA, Harvard, Vancouver, ISO, and other styles
3

PAUL, Corina, Camelia EPURE, and Iulian VELEA. "P58 Growth hormone therapy for total growth hormone deficiency after complete therapy for parameningeal rhabdomyosarcoma." In 8th Europaediatrics Congress jointly held with, The 13th National Congress of Romanian Pediatrics Society, 7–10 June 2017, Palace of Parliament, Romania, Paediatrics building bridges across Europe. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2017. http://dx.doi.org/10.1136/archdischild-2017-313273.146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Caldwell, Jon-Michael E., Ryan T. Cassilly, Haley A. Bunting, Christopher S. Ahmad, Louis U. Bigliani, William N. Levine, and Thomas R. Gardner. "Effects of Hormone Therapy on Regional Surface Strain as a Function of Applied Strain in the Macaque Inferior Glenohumeral Ligament." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80840.

Full text
Abstract:
Hormones such as estrogen are known to have an effect on the biomechanical properties of certain ligaments such as the anterior cruciate ligament in the knee; however, relatively little is known about its effect on the ligaments of the shoulder. The inferior glenohumeral ligament (IGHL) is a static stabilizer of the shoulder that prevents anterior translation of the humeral head. Alterations to the properties of this ligament can result in capsular stretching, increased laxity, and ultimately instability. The cynomolgus macaque (Macaca fascicularis) shares many hormonal similarities with humans including a 28-day menstrual cycle and is a commonly used model for hormone replacement therapy studies. This study uses the female cynomolgus monkey as a model of the human shoulder to determine if estrogen has an effect on the regional surface strain behavior of the inferior glenohumeral ligament.
APA, Harvard, Vancouver, ISO, and other styles
5

Zhang, P., and J. G. Zein. "Menopausal Hormone Replacement Therapy and Risk of Asthma." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vieira, Amanda Cristina de Souza, Antônio Pedro Oliveira de Vasconcelos, Jaqueline Maria Pinheiro de Araujo, Juliana Comin Müller, Larissa de Cassia Afonso Magalhães, Renato Duarte da Silva, Ricardo Baroni Vieira, and Fabiana Candida de Queiroz Santos Anjos. "EPIDEMIOLOGICAL RELATIONSHIP BETWEEN HORMONE REPLACEMENT THERAPY AND BREAST CANCER." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2090.

Full text
Abstract:
Objective: The aim of this study was to epidemiologically analyze the hormone replacement therapy (HRT) and the emergence of breast cancer. Methodology: This is an article review from the databases such as LILACS, SciELO, Bireme, and Medscape, utilizing the keywords: menopause, HRT, breast cancer and complications, employing the use of connectors when necessary. This review aims to elucidate what has been published in the last years about the usage of hormone therapy and the emergence of breast cancer since there are disagreements between the literature. Results: The analysis displayed positive effects during the usage of HRT, such as maintenance of bone density, prevention of fractures, and cardiovascular events in patients with no previous changes in this system, and also showed us a strong relationship between HRT and the incidence of breast cancer in menopausal women with a focus into the imposing time of use ratio. Meanwhile, this development risk of breast CA can be reduced in the long run with the withdrawal of the previously initiated therapy. The progesterone HRT has been shown to have lower risks in association with estrogen than when compared with the association of synthetic progestins and estrogen. Associations have similar results for oral and skin HRT. In patients using the postmenopausal hormone therapy, the risk of mortality from breast cancer was reduced in patients with exposure for a maximum of 5 years, more than 5–10 years, or more than 10 years. Conclusion: In view of the exposure, it is considered that the HRT is more beneficial than malefic to the life and health of women. Meanwhile, the risk of breast CA goes up while the HRT time stretches over the years. Thus, it is necessary to individually evaluate the benefits and risks to better identify the therapy that should be utilized.
APA, Harvard, Vancouver, ISO, and other styles
7

Roehrs, Susanne. "Fluorescence detection of MSH-receptors in melanoma as a target of hormone-directed photosensitation in PDT." In Photodynamic Therapy of Cancer II. SPIE, 1995. http://dx.doi.org/10.1117/12.199162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chandrasekharan Nair, B., SS Nair, D. Chakravarty, RP Yew, RR Tekmal, and RK Vadlamudi. "Modulation of hormone therapy resistance by CDK2-PELP1 axis." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ms Julia Gao. "Psoriasis and PsA in transgender adults on hormone therapy." In WPPAC 2021. Baarn, the Netherlands: Medicom Medical Publishers, 2021. http://dx.doi.org/10.55788/644c5208.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Triebner, Kai, Simone Accordini, Lucia Calciano, Ane Johannessen, Bryndís Benediktsdóttir, Ersilia Bifulco, Pascal Demoly, et al. "Hormone replacement therapy may preserve lung function during reproductive aging." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa4420.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Hormone therapy"

1

Huang, Xi. Hormone Replacement Therapy, Iron, and Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2005. http://dx.doi.org/10.21236/ada448472.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Huang, Xi. Hormone Replacement Therapy, Iron, and Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, November 2004. http://dx.doi.org/10.21236/ada433028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chung, Ivy. Benzimidazole as Novel Therapy for Hormone-Refractory Metastatic Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2011. http://dx.doi.org/10.21236/ada545657.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Thomas P Quinn. Melanoma Therapy with Rhenium-Cyclized Alpha Melanocyte Stimulating Hormone Peptide Analogs. Office of Scientific and Technical Information (OSTI), November 2005. http://dx.doi.org/10.2172/951315.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Manosroi, Worapaka, and Pichitchai Atthakomol. Hormone replacement therapy and risk of carpal tunnel syndrome: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Diefenbach, Michael A. An Intervention to Control Vasomotor Symptoms for Advanced PC Patients on Hormone Therapy. Fort Belvoir, VA: Defense Technical Information Center, August 2014. http://dx.doi.org/10.21236/ada613257.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nair, Binoj. Evaluating the Significance of CDK2-PELP1 Axis in Tumorigenesis and Hormone Therapy Resistance. Fort Belvoir, VA: Defense Technical Information Center, February 2011. http://dx.doi.org/10.21236/ada542782.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nair, Binoj. Evaluating the Significance of CDK2-PELP1 Axis in Tumorigenesis and Hormone Therapy Resistance. Fort Belvoir, VA: Defense Technical Information Center, February 2010. http://dx.doi.org/10.21236/ada542787.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Diefenbach, Michael A. An Intervention to Control Vasomotor Symptoms for Advanced PC Patients on Hormone Therapy. Fort Belvoir, VA: Defense Technical Information Center, August 2012. http://dx.doi.org/10.21236/ada566715.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Diefenbach, Michael A. An Intervention to Control Vasomotor Symptoms for Advanced PC Patients on Hormone Therapy. Fort Belvoir, VA: Defense Technical Information Center, August 2013. http://dx.doi.org/10.21236/ada591496.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hormone therapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography